Pulsenmore Posts Revenue Growth Amid U.S. Expansion Push — Pulsenmore Ltd.

Event summary

Pulsenmore reported a 53% revenue increase to NIS 6.1M ($2M) in H1 2026, driven by higher device sales and new product recognition.
The company signed first U.S. commercial agreements with two perinatal care providers and launched its U.S. e-commerce platform.
Pulsenmore secured $1.67M in AI grants from Israel Innovation Authority for two healthcare programs.
Operating loss widened slightly to NIS 20.8M ($7M) due to commercialization and development expenses.
Cash position grew to NIS 70M ($23.4M) following a $7.5M private placement in June 2026.

The big picture

Pulsenmore's H1 2026 results reflect its strategic shift toward U.S. market expansion following FDA approval. The company's focus on remote maternal-fetal healthcare aligns with broader trends in digital health and telemedicine adoption. With $23.4M in cash and strategic partnerships in place, Pulsenmore aims to scale its commercial operations while managing operating losses. The $1.67M in AI grants underscores Israel's support for healthcare innovation, positioning Pulsenmore for potential regulatory and technological advantages.

What we're watching

U.S. Market Penetration: Whether Pulsenmore can sustain its commercial momentum in the U.S. following FDA authorization and initial partnerships.
Regulatory Expansion: The pace at which the company secures additional regulatory clearances for its ES Tera product line.
Manufacturing Scaling: How Pulsenmore's planned automated manufacturing operations in Israel will impact production capacity and costs.